Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Selects GSK’s Saynor As Next Sandoz CEO

Executive Summary

GlaxoSmithKline’s established products head, Richard Saynor, will return to Sandoz later this year to lead the Novartis division.

You may also be interested in...



Saynor Seeks To Take Sandoz Back To Basics

In an exclusive interview with Generics Bulletin, Sandoz’ CEO Richard Saynor explains how he wants the Novartis division to focus on the industry basics of being first-to-market with cost-competitive generics and biosimilars.

Sandoz Breaks Off Digital Deal With Pear

Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.

Novartis Sees Space For Sandoz But In A Slimmer Streamlined Form

Sandoz has a place within Novartis as a more autonomous unit, the Swiss group’s CEO Vas Narasimhan says. But the generics and biosimilars division will have to sharpen up, aided by a 7% workforce cut.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB140269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel